→ So why would Trump attorney Michael Cohen reach out to sell his services to Novartis, but ignore the big Basel rival Roche? “I have asked internally if we had any contact, and that is not the case,” Severin Schwan told Reuters.
→ A booming WuXi Biologics is building a new complex in Shijiazhuang, China that will expand its operations in research, development and manufacturing. Its new manufacturing ops will be built to global cGMP standards. “We are very pleased to establish the largest biologics center in northern China, which will enable local companies to more effectively develop and manufacture biologics and in the meantime provide a robust supply chain network for our global clients. This expansion will allow us great access to local talents, markets and government support,” said Chris Chen, the CEO of WuXi Biologics.
→ Following a makeover after a major clinical flop, Cambridge, MA-based Eleven Biotherapeutics is changing its name and stock symbol. The company now goes by Sesen Bio, converting its ticker from $EBIO to $SESN. The branding change makes sense, considering Eleven was little more than a shell with a bank account a couple years ago after its lead drug failed twice and it completed a deal to license out its remaining program to Roche. But then the entity acquired Toronto-based Viventia Bio, snagging its now lead drug candidate vicinium, a next-gen antibody-drug conjugate to treat high-grade non-muscle invasive bladder cancer. “Over the last several years, we have undergone an incredible transformation as a company, and our new name, Sesen Bio, reinforces this evolution and our focused commitment to oncology drug development,” said Stephen Hurly, Sesen’s president and CEO, in a statement. “Sesen, an ancient symbol of the lotus flower, represents life and our mission to bring forward medicines that will improve and preserve the lives of those with devastating cancers.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 34,800+ biopharma pros who read Endpoints News by email every day.Free Subscription